[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DE602005006758D1 - Il-4/il-13-spezifische polypetide und deren therapeutische verwendung - Google Patents

Il-4/il-13-spezifische polypetide und deren therapeutische verwendung

Info

Publication number
DE602005006758D1
DE602005006758D1 DE602005006758T DE602005006758T DE602005006758D1 DE 602005006758 D1 DE602005006758 D1 DE 602005006758D1 DE 602005006758 T DE602005006758 T DE 602005006758T DE 602005006758 T DE602005006758 T DE 602005006758T DE 602005006758 D1 DE602005006758 D1 DE 602005006758D1
Authority
DE
Germany
Prior art keywords
therapeutic use
specific polypeptides
polypeptides
interluekin
specific
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE602005006758T
Other languages
English (en)
Inventor
Margaret Karow
Jeanette Fairhurst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of DE602005006758D1 publication Critical patent/DE602005006758D1/de
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5437—IL-13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5406—IL-4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE602005006758T 2004-02-27 2005-02-25 Il-4/il-13-spezifische polypetide und deren therapeutische verwendung Expired - Fee Related DE602005006758D1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54854104P 2004-02-27 2004-02-27
US60213904P 2004-08-17 2004-08-17
US62834304P 2004-11-16 2004-11-16
PCT/US2005/006266 WO2005085284A1 (en) 2004-02-27 2005-02-25 Il-4/il-13 sepecific polypetides and therapeutic uses thereof

Publications (1)

Publication Number Publication Date
DE602005006758D1 true DE602005006758D1 (de) 2008-06-26

Family

ID=34923259

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005006758T Expired - Fee Related DE602005006758D1 (de) 2004-02-27 2005-02-25 Il-4/il-13-spezifische polypetide und deren therapeutische verwendung

Country Status (9)

Country Link
US (1) US7410781B2 (de)
EP (1) EP1723173B1 (de)
JP (1) JP2008504806A (de)
AT (1) ATE395358T1 (de)
AU (1) AU2005219837A1 (de)
CA (1) CA2554596A1 (de)
DE (1) DE602005006758D1 (de)
IL (1) IL176967A0 (de)
WO (1) WO2005085284A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0710572A2 (pt) * 2006-01-24 2013-01-08 Domantis Ltd ligante, uso do ligante, mÉtodos para o tratamento de uma doenÇa alÉrgica, de asma e de cÂncer, para a inibiÇço de uma resposta imune do tipo th2, e administraÇço de tratamento anti-il-4 e tratamento anti-il-13, composiÇço farmacÊutica, dispositivo de dispensaÇço de droga, Ácido nucleico isolado ou recombinante, vetor, cÉlula hospedeira, mÉtodos para a produÇço de um ligante e de inibiÇço da proliferaÇço de cÉlulas
CN101512008B (zh) 2006-09-08 2015-04-01 艾伯维巴哈马有限公司 白介素-13结合蛋白
ES2466669T3 (es) * 2006-10-02 2014-06-10 Regeneron Pharmaceuticals, Inc. Anticuerpos humanos con alta afinidad para el receptor IL-4 humano
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
JP2014510730A (ja) 2011-03-16 2014-05-01 サノフイ デュアルｖ領域抗体様タンパク質の使用
NZ783258A (en) 2012-08-21 2023-06-30 Regeneron Pharma Methods for treating or preventing asthma by administering an il-4r antagonist
TWI697334B (zh) 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
WO2014205365A1 (en) 2013-06-21 2014-12-24 Sanofi Methods for treating nasal polyposis by administering an il-4r antagonist
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by adding an IL-4R antagonist
EP3110848B1 (de) 2014-02-28 2024-02-14 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung einer hautinfektion durch verabreichung eines il-4r-antagonisten
WO2016044707A1 (en) * 2014-09-18 2016-03-24 Cedars-Sinai Medical Center Compositions and methods for treating fibrosis
EP3218412A1 (de) 2014-11-14 2017-09-20 Sanofi Biotechnology Verfahren zur behandlung von chronischer sinusitis mit nasenpolypen durch verabreichung eines il-4r-antagonisten
EA202190162A3 (ru) 2016-04-27 2021-11-30 Эббви Инк. Способы лечения заболеваний, при которых активность il-13 оказывает негативное влияние, с применением антител против il-13
PT3506931T (pt) 2016-09-01 2024-08-21 Regeneron Pharma Métodos de prevenção ou de tratamento da alergia mediante a administração de um antagonista de il-4r
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
JP2020517262A (ja) * 2017-04-21 2020-06-18 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医学的使用のためのｉｌ４／ｉｌ１３受容体分子
US11053309B2 (en) 2017-08-04 2021-07-06 Regeneron Pharmaceuticals, Inc. Methods for treating active eosinophilic esophagitis
PT3515465T (pt) 2017-08-18 2024-03-04 Regeneron Pharma Métodos para o tratamento de uma dermatite atópica grave mediante a administração de um inibidor de il-4r
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN112153982A (zh) 2018-05-13 2020-12-29 瑞泽恩制药公司 用于通过施用il-4r抑制剂治疗特应性皮炎的方法
WO2020086886A1 (en) * 2018-10-25 2020-04-30 Kindred Biosciences, Inc. Il4/il13 receptor molecule for veterinary use
MA55372A (fr) 2019-03-21 2022-01-26 Regeneron Pharma Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
NL2022982B1 (en) * 2019-04-19 2020-10-27 Synerkine Pharma B V A fusion protein comprising IL13
GB2620875B (en) * 2019-04-19 2024-05-08 Synerkine Pharma B V A fusion protein comprising IL13
EP4010373A1 (de) 2019-08-05 2022-06-15 Regeneron Pharmaceuticals, Inc. Verfahren zur behandlung atopischer dermatitis durch verabreichung eines il-4r-antagonisten
US11504426B2 (en) 2019-08-05 2022-11-22 Regeneron Pharmaceuticals, Inc. Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an IL-4R antagonist
CN116323659A (zh) * 2020-06-12 2023-06-23 北京伟德杰生物科技有限公司 融合多肽

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
AU2003243189B2 (en) 2002-05-01 2008-01-24 Regeneron Pharmaceuticals, Inc. Methods of using cytokine antagonists to treat HIV infection and AIDS

Also Published As

Publication number Publication date
US7410781B2 (en) 2008-08-12
EP1723173B1 (de) 2008-05-14
US20050191730A1 (en) 2005-09-01
IL176967A0 (en) 2006-12-10
JP2008504806A (ja) 2008-02-21
AU2005219837A1 (en) 2005-09-15
ATE395358T1 (de) 2008-05-15
CA2554596A1 (en) 2005-09-15
WO2005085284A1 (en) 2005-09-15
EP1723173A1 (de) 2006-11-22

Similar Documents

Publication Publication Date Title
DE602005006758D1 (de) Il-4/il-13-spezifische polypetide und deren therapeutische verwendung
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
CY1115524T1 (el) Ανθρωπινα μονοκλωνικα αντισωματα εναντι της ανθρωπινης il-4
MX2009007406A (es) Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
EA200801515A1 (ru) Лиганды, которые связывают il-4 и/или il-13
ATE389649T1 (de) Substituierte amin-derivate und deren verwendung zur behandlung von angionese-bedingten erkrankungen
DK1917246T3 (da) Benzoquinazolinderivater og deres anvendelse til behandling af knoglesygdomme
DK1799235T3 (da) Sammensætninger af fosterhudcelleprotein til behandling af hudtilstande, -lidelser eller -sygdomme og fremgangsmåder til fremstilling og anvendelse deraf
ATE452908T1 (de) Il-10 mutante
DK1998805T3 (da) Tumorterapi med et antistof til vaskulær endotelial vækstfaktor og et antistof til human epitelial vækstfaktor receptor type 2
GB0713654D0 (en) Methods for expression and purification of recombinant human growth hormone
NO20081842L (no) Fremgangsmåter og sammensetninger for anvendelse ved behandling av pasienter med autoantistoff-positive sykdommer
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DK1994157T3 (da) Rekombinante humane epo-fc-fusionsproteiner med forlænget halveringstid og forstærket erythropoietisk aktivitet in vivo
ATE495179T1 (de) Tetrahydropyridothienpyrimidin-verbindungen und verwendung zur behandlung proliferativer erkrankungen
IS7348A (is) N-pýrasínýl-fenýlsúlfónamíð og notkun þeirra til að meðhöndla flakkboðatengda sjúkdóma
DK1575951T3 (da) Heterocykliske forbindelser, fremgangsmåder til fremstilling deraf og deres anvendelse i terapi
DE602005009255D1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
DE602006019849D1 (de) Proteinspaltungsverfahren und verwendung davon
DK1745069T3 (da) Terapeutisk anvendelse af vækstfaktoren NSG33
WO2007018879A3 (en) Interferon-gamma antagonists and therapeutic uses thereof
WO2006138610A3 (en) Interferon-alpha/beta binding fusion proteins and therapeutic uses thereof
ATE518531T1 (de) Alpha-humulene zur verwendung bei der prophylaxe oder behandlung der entzündlichen schmerzen und des ödems
ATE469659T1 (de) Stibogluconate-natrium und il-2 zur krebsbehandlung
ATE479716T1 (de) Copolymerisate und ihre verwendung zur behandlung von flexiblen substraten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee